A Multicenter, Phase 2 Study of Ibrutinib plus FCR as Frontline Therapy for Younger Patients with CLL
A multicenter phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab (FCR) as frontline therapy for younger patients with relatively high-risk chronic lymphocytic leukemia (CLL) showed that this combination resulted in superior rates of complete remission and bone marrow minimal residual disease negativity compared with FCR alone, with acceptable levels of toxicity.
Initial Results of the Phase 2 Treatment-Naïve Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL
The combination of obinutuzumab, ibrutinib, and venetoclax for 25 treatment-naïve patients with chronic lymphocytic leukemia (CLL) was safe and resulted in a 96% overall response rate, with a 52% rate of complete remission and a 58% rate of minimal residual disease negativity in blood and bone marrow after 8 cycles of therapy.
Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
Economic Evaluation for the United States of Ibrutinib versus Allogeneic HSCT for Patients with Relapsed or Refractory CLL with 17p Deletion
In a cost-effectiveness and cost-utility analysis of ibrutinib versus allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with relapsed/refractory CLL with del(17p), ibrutinib provides significantly greater clinical and economic value over the first 3 years of treatment, but the benefit declines beyond 3 years.
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: Updated Results from the Phase 1/2 ACE-CL-001 Study
In an update of the phase 1/2 ACE-CL-001 study, patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma treated with acalabrutinib monotherapy demonstrated high response rates (overall response, 85%; 18-month duration of response, 85%; 18-month progression-free survival, 88%), with an acceptable safety profile.
Long-Term Follow-Up of ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel in Patients with Refractory, Aggressive NHL
In a 1-year follow-up of the ZUMA-1 study, axicabtagene ciloleucel (axi-cel; anti-CD19 CAR T) demonstrated significant clinical benefit with manageable adverse events in patients with refractory, aggressive non-Hodgkin lymphoma (NHL) and no curative treatment options, but loss of CD19 and gain of PD-L1 expression in tumors were identified as possible mechanisms of resistance following axi-cel treatment.
Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or CLL
The combination of ibrutinib plus nivolumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma was safe but not more effective than ibrutinib alone. It did, however, demonstrate superior efficacy in patients with Richter’s transformation, although the study did not select patients with elevated PD-L1 levels.
Single-Agent Ibrutinib versus Chemoimmunotherapy Regimens for Treatment-Naïve Patients with CLL: A Cross-Trial Comparison
Prolonged Improvement in PROs and Well-Being in Older Patients with Treatment-Naïve CLL Treated with Ibrutinib: 3-Year Follow-Up of the RESONATE-2 Study
In the RESONATE-2 study, treatment of older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia resulted in significantly improved patient-reported outcomes (PROs), disease burden, quality of life, medical resource utilization, and quality-adjusted survival time compared with those treated with chlorambucil.
Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle-Cell Lymphoma: A Pooled Analysis
Page 6 of 19
Results 51 - 60 of 190
Results 51 - 60 of 190